Literature DB >> 26855807

Proton pump inhibitor prescription abuse and sepsis in cirrhosis.

Antonio Picardi1, Umberto Vespasiani-Gentilucci1.   

Abstract

Proton pump inhibitors (PPIs) represent one of the most extensively prescribed classes of drugs in general and in patients with liver cirrhosis. Many prescriptions are made without a clear adherence to standard indications. As a class of ordinarily well tolerated drug, PPIs are not free of side-effects and concerns have been raised about a possible role for PPIs in predisposing patients to an increased risk of bacterial infections and sepsis. As evidences of different power are accumulating on this topic, prospective studies are needed to reach a more universal agreement, but definitely more attention is needed by prescribers in being more adherent to the few recognized indications for the use of PPIs, particularly in patients with liver cirrhosis. Otherwise, doctors could run the risk of being accused of "abused" prescription.

Entities:  

Keywords:  Bacterial infection; Liver cirrhosis; Proton pump inhibitors; Sepsis

Year:  2016        PMID: 26855807      PMCID: PMC4734942          DOI: 10.4292/wjgpt.v7.i1.1

Source DB:  PubMed          Journal:  World J Gastrointest Pharmacol Ther        ISSN: 2150-5349


  36 in total

1.  Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies.

Authors:  S E Attwood; C Ell; J P Galmiche; R Fiocca; J G Hatlebakk; B Hasselgren; G Långström; M Jahreskog; S Eklund; T Lind; L Lundell
Journal:  Aliment Pharmacol Ther       Date:  2015-04-10       Impact factor: 8.171

Review 2.  Proton pump inhibitors: the good, the bad, and the unwanted.

Authors:  Saman Chubineh; John Birk
Journal:  South Med J       Date:  2012-11       Impact factor: 0.954

3.  Aspiration of gastric bacteria in antacid-treated patients: a frequent cause of postoperative colonisation of the airway.

Authors:  G C du Moulin; D G Paterson; J Hedley-Whyte; A Lisbon
Journal:  Lancet       Date:  1982-01-30       Impact factor: 79.321

4.  Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis.

Authors:  G Dultz; A Piiper; S Zeuzem; B Kronenberger; O Waidmann
Journal:  Aliment Pharmacol Ther       Date:  2014-12-19       Impact factor: 8.171

Review 5.  Omeprazole. Overview and opinion.

Authors:  S Holt; C W Howden
Journal:  Dig Dis Sci       Date:  1991-04       Impact factor: 3.199

6.  Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis.

Authors:  M Isabel Lucena; Raúl J Andrade; Gianni Tognoni; Ramón Hidalgo; Felipe Sanchez De La Cuesta
Journal:  Eur J Clin Pharmacol       Date:  2002-07-10       Impact factor: 2.953

7.  Improved survival after variceal bleeding in patients with cirrhosis over the past two decades.

Authors:  Nicolas Carbonell; Arnaud Pauwels; Lawrence Serfaty; Olivier Fourdan; Victor George Lévy; Raoul Poupon
Journal:  Hepatology       Date:  2004-09       Impact factor: 17.425

Review 8.  Proton pump inhibitors in cirrhosis: tradition or evidence based practice?

Authors:  Francesca Lodato; Francesco Azzaroli; Maria Di Girolamo; Valentina Feletti; Paolo Cecinato; Andrea Lisotti; Davide Festi; Enrico Roda; Giuseppe Mazzella
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

9.  Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy.

Authors:  Lucio Lombardo; Monica Foti; Olga Ruggia; Andrea Chiecchio
Journal:  Clin Gastroenterol Hepatol       Date:  2010-01-06       Impact factor: 11.382

Review 10.  Review article: prescribing medications in patients with cirrhosis - a practical guide.

Authors:  J H Lewis; J G Stine
Journal:  Aliment Pharmacol Ther       Date:  2013-05-03       Impact factor: 8.171

View more
  2 in total

Review 1.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

2.  The Association of Long-Term Use of Proton Pump Inhibitors and Histamine H2 Receptor Antagonists with Clinical Complications in Patients with Severe Sepsis.

Authors:  Jiamin Gao; Senlin Ma; Siyuan Xu; Mingquan Chen
Journal:  Dis Markers       Date:  2022-06-28       Impact factor: 3.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.